- Molecular NameCefacetrile
- Synonym7-Cyanacetylamino-cephalosporansaeure; Cefacetrilo [inn-spanish]; Cefacetrilum [inn-latin]; Cephacetrile
- Weight339.328
- Drugbank_IDDB01414
- ACS_NO10206-21-0
- Show 2D model
- LogP (experiment)0.35
- LogP (predicted, AB/LogP v2.0)-0.78
- pka1.5, 7.2
- LogD (pH=7, predicted)-4.77
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.47
- LogSw (predicted, AB/LogsW2.0)85.39
- Sw (mg/ml) (predicted, ACD/Labs)0.16
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds7
- TPSA162.1
- StatusFDA approved
- AdministrationIntravenous, intramuscular
- PharmacologyA broad-spectrum first generation cephalosporin antibiotic effective in Gram-positive and Gram-negative bacterial infections. It is a bacteriostatic antibiotic.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding25.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life0.5~1 h; 2.3~2.8 h in patients with the complete absence of renal function. Serum, 0.6 to 0.9 h; slightly prolonged in patients with renal impairment.
- ExcretionRenal (72%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A